Acute Kidney Injury After Craniocerebral Operation

Sponsor
Beijing Tiantan Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT03789747
Collaborator
(none)
143
1
39.9
3.6

Study Details

Study Description

Brief Summary

The aim of this study was to report the incidence, severity and risk factors of acute kidney injury (AKI) in patients underwent craniocerebral operation and admitted into intensive care unit (ICU).

Condition or Disease Intervention/Treatment Phase
  • Other: As a observational study, there is no intervention.

Detailed Description

The study included consecutive adult patients who underwent craniotomy and admitted into intensive care unit (ICU) between January 2017 and December 2018. Patients with congenital renal abnormalities or with stages 4 and 5 chronic kidney disease (CKD) were excluded. Serum creatinine levels were measured before operation, daily after operation until discharged from ICU ward . AKI was depicted according to changes in early postoperative serum creatinine levels and its severity was determined based on the Acute Kidney Injury Network (AKIN) classification. Univariate and multivariate statistical analyses were conducted to determine risk factors for developing AKI.

Preoperative, intraoperative and postoperative variables known to be or could potentially be associated with AKI or other adverse outcomes were collected. Preoperation variables include age, gender, weight, hypertension, diabetes mellitus, hyperuricemia, proteinuria, preoperative serum Cr and estimated estimated glomerular filtration rate (eGFR), left ventricular ejection fraction (LVEF), Charlson Comorbidity Index (CCI), emergency surgery and intravenous contrast. eGFR was calculated with MDRD4 equation. Proteinuria was defined as protein > 15 mg/dl in spot urine specimens. Hyperuricemia was defined as a serum uric acid > 6.6 in women and > 7.0 mg/dl in men. Patients were considered to have diabetes if they were diagnosed with type 1 or type 2 diabetes mellitus before or were taking insulin or oral hypoglycemic agents at the time of cardiac surgery. Hypertension was defined as SBP > 140 mm Hg and/or DBP > 90 mm Hg; or had hypertension history and were taking antihypertensive drugs. LVEF was assessed preoperatively by echocardiography. Charlson Comorbidity Index was used to measure comorbid disease status by calculating the comorbidity score.

Intra-operative variables include surgery type, duration of operation, blood transfusion, urine output,the highest and lowest mean blood pressures, use of radiocontrast agents and dehydrants.

Postoperation variables include hypotension, central venous pressure (CVP), oliguria, re-exploration, mechanical ventilation, use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB), radiocontrast agents, dehydrants and RRT. Hypotension was defined as SBP < 90 mm Hg postoperative but before the diagnosis of AKI.

Patients were followed until discharge and all-cause in-hospital mortality was recorded. The length of stay in the ICU and hospital was also recorded. The mortality rates of the patients with or without AKI were compared.

Continuous variables were expressed as mean (SD) and analyzed by unpaired Student's t test. Nonparametric variables were expressed as median and 25-75% percentiles and analyzed by the Mann-Whitney test. Categorical variables were expressed as absolute (n) and relative (%) frequency and were analyzed by chi-square test, as appropriate. A multivariate logistic regression model incorporating all factors associated with AKI in univariate analysis as well as those factors showing a univariate p value < 0.05 was performed to identify associated risk factors with AKI, while Cox Proportional Hazards model was used to identify associated factors with in-hospital mortality and hazard ratios. Risk data are presented as odds or hazard ratios with 95% CIs. p < 0.05 was considered statistically significant for all comparisons. SPSS version 19.0 for windows software was used for the statistical analysis.

Study Design

Study Type:
Observational
Actual Enrollment :
143 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Incidence and Risk Factors of Acute Kidney Injury After Craniocerebral Operation: A Single-Center Experience
Actual Study Start Date :
Jan 1, 2017
Actual Primary Completion Date :
Dec 31, 2018
Actual Study Completion Date :
Apr 30, 2020

Outcome Measures

Primary Outcome Measures

  1. Incidence and outcome of AKI after Craniotomy [1 month]

    All adult patients who underwent craniotomy and admitted into intensive care unit (ICU) between January 2017 and December 2018 were screened for acute kidney injury.

Secondary Outcome Measures

  1. Risk factors for AKI after Craniotomy [1 month]

    Preoperative, intraoperative and postoperative variables known to be or could potentially be associated with AKI or other adverse outcomes were collected. A multivariate logistic regression model incorporating all factors associated with AKI in univariate analysis as well as those factors showing a univariate p value < 0.05 was performed to identify associated risk factors with AKI.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients underwent craniocerebral surgery;

  • admitted into ICU ward.

Exclusion Criteria:
  • Age< 18 years;

  • Patients with congenital renal abnormities or with stages 4 and 5 chronic kidney disease (CKD).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Beijing Tian Tan hospital Beijing Beijing China 100050

Sponsors and Collaborators

  • Beijing Tiantan Hospital

Investigators

  • Study Director: Jianxin Zhou, MD, Beijing Tian Tan Hospital
  • Study Director: Guangzhi Shi, MD, Beijing Tian Tan Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jianfang Zhou, Principal investigator, Beijing Tiantan Hospital
ClinicalTrials.gov Identifier:
NCT03789747
Other Study ID Numbers:
  • Beijing Tiantan Hospital
First Posted:
Dec 31, 2018
Last Update Posted:
Aug 5, 2021
Last Verified:
Aug 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jianfang Zhou, Principal investigator, Beijing Tiantan Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 5, 2021